These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 29255527)

  • 1. A pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinoma.
    Naiki T; Iida K; Kawai N; Etani T; Ando R; Nagai T; Tanaka Y; Hamamoto S; Hamakawa T; Akita H; Sugiyama Y; Yasui T
    J Rural Med; 2017 Nov; 12(2):105-111. PubMed ID: 29255527
    [No Abstract]   [Full Text] [Related]  

  • 2. Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis.
    Naiki T; Iida K; Etani T; Nagai T; Tanaka Y; Sugiyama Y; Ando R; Hamamoto S; Banno R; Nagata D; Kawai N; Yasui T
    Cancer Manag Res; 2018; 10():3669-3677. PubMed ID: 30271215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential therapy with gemcitabine and Carboplatin followed by Paclitaxel as first line treatment for advanced urothelial cancer.
    Kattan JG; Boutros CY; Farhat FS; Chahine GY; Musallam KM; Ghosn MG
    J Cancer; 2012; 3():362-8. PubMed ID: 23074377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy.
    Furubayashi N; Negishi T; Yamashita T; Kusano S; Taguchi K; Shimokawa M; Nakamura M
    Mol Clin Oncol; 2017 Dec; 7(6):1112-1118. PubMed ID: 29285384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy.
    Kobayashi K; Matsuyama H; Shimizu K; Fujii N; Inoue R; Yamamoto Y; Matsumoto H; Nagao K
    Jpn J Clin Oncol; 2016 Aug; 46(8):775-80. PubMed ID: 27272172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of relative dose intensity in gemcitabine-cisplatin chemotherapy for metastatic urothelial carcinoma.
    Kohei N; Sugiyama K; Chihara I; Muro Y; Imamura M; Nishio Y; Yoshimura K
    SAGE Open Med; 2018; 6():2050312118783011. PubMed ID: 30013781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
    Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
    Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.
    Joung JY; Kwon WA; Cho IC; Kim EK; Park S; Yoon H; Seo HK; Chung J; Park WS; Lee KH
    Int J Urol; 2011 May; 18(5):350-7. PubMed ID: 21355894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.
    Kakutani S; Fukuhara H; Taguchi S; Nagata M; Niimi A; Hattori M; Miyazaki H; Fujimura T; Nakagawa T; Kume H; Igawa Y; Homma Y
    Jpn J Clin Oncol; 2015 Mar; 45(3):281-5. PubMed ID: 25425701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer.
    Yun T; Kim HT; Han JY; Yoon SJ; Kim HY; Nam BH; Lee JS
    Cancer Res Treat; 2016 Apr; 48(2):465-72. PubMed ID: 26044164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
    Chen YM; Shih JF; Lee CS; Chen MC; Lin WC; Tsai CM; Perng RP
    Lung Cancer; 2003 Feb; 39(2):209-14. PubMed ID: 12581575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment.
    Lee JH; Kang SG; Kim ST; Kang SH; Choi IK; Park YJ; Oh SC; Sung DJ; Seo JH; Cheon J; Shin SW; Kim YH; Kim JS; Park KH
    Cancer Res Treat; 2014 Apr; 46(2):172-7. PubMed ID: 24851109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine maintenance versus observation after first-line chemotherapy in patients with metastatic urothelial carcinoma: a retrospective study.
    Kim H; Lee SH; Kim DH; Lee JY; Hong SH; Ha US; Kim IH
    Transl Androl Urol; 2020 Oct; 9(5):2113-2121. PubMed ID: 33209674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma.
    Furubayashi N; Negishi T; Takamatsu D; Ieiri K; Inoue T; Tsukino K; Nakamura M
    Oncol Lett; 2020 Apr; 19(4):2943-2949. PubMed ID: 32256805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer.
    Sideris S; Aoun F; Zanaty M; Martinez NC; Latifyan S; Awada A; Gil T
    Mol Clin Oncol; 2016 Jun; 4(6):1063-1067. PubMed ID: 27284445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Case of Metastatic Urothelial Carcinoma Treated with Pemetrexed as Third-Line Chemotherapy with Discussion and Literature Review.
    Iida K; Kawai N; Naiki T; Etani T; Ando R; Nagai T; Sugiyama Y; Naiki-Ito A; Nishio H; Okada A; Kohri K; Yasui T
    Case Rep Oncol; 2015; 8(3):530-5. PubMed ID: 26668577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of tolerability and quality of life for carboplatin-based chemotherapy in an elderly urothelial carcinoma patient undergoing hemodialysis: a case report.
    Kondo M; Naiki T; Hotta Y; Yamamoto Y; Sugiyama Y; Yasui T; Kimura K
    J Pharm Health Care Sci; 2018; 4():29. PubMed ID: 30519478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation.
    Cao JZ; Wu W; Pan JF; Wang HW; Jiang JH; Ma Q
    Front Oncol; 2021; 11():643413. PubMed ID: 34109111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically meaningful responses to sequential gemcitabine-based chemotherapy regimens in a patient with metastatic pancreatic cancer.
    Klimant E; Markman M; Albu DM
    Case Rep Oncol; 2013 Jan; 6(1):72-7. PubMed ID: 23466899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data.
    Fischer C; Hofmann R; Hegele A
    Cancer Manag Res; 2020; 12():5077-5084. PubMed ID: 32636673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.